Shares of Novozymes A/S (OTCMKTS:NVZMY - Get Free Report) passed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $62.20 and traded as high as $70.65. Novozymes A/S shares last traded at $70.09, with a volume of 7,843 shares trading hands.
Novozymes A/S Trading Down 1.0%
The firm's fifty day moving average price is $62.78 and its 200 day moving average price is $59.42. The firm has a market capitalization of $32.66 billion, a PE ratio of 44.15, a P/E/G ratio of 3.87 and a beta of 0.92.
Novozymes A/S Increases Dividend
The business also recently declared a dividend, which was paid on Wednesday, April 23rd. Investors of record on Monday, April 7th were given a dividend of $0.3758 per share. This is a boost from Novozymes A/S's previous dividend of $0.17. The ex-dividend date was Monday, April 7th. Novozymes A/S's dividend payout ratio (DPR) is currently 47.47%.
About Novozymes A/S
(
Get Free Report)
Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.
See Also
Before you consider Novozymes A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novozymes A/S wasn't on the list.
While Novozymes A/S currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
